BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kunz U, Goodman J, Loevgren U, Piironen T, Elsby K, Robinson P, Pihl S, Versteilen A, Companjen A, Fjording MS, Timmerman P. Addressing the challenges of biomarker calibration standards in ligand-binding assays: a European Bioanalysis Forum perspective. Bioanalysis 2017;9:1493-508. [PMID: 29056059 DOI: 10.4155/bio-2017-0141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Arnold ME. An industry perspective on the US FDA biomarker qualification effort. Bioanalysis 2018;10:913-6. [DOI: 10.4155/bio-2018-0049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Hays A, Amaravadi L, Fernandez-Metzler C, King L, Mathews J, Ni Y, Quadrini K, Tinder C, Vazvaei F, Zeng J. Is Incurred Sample Reanalysis (ISR) Applicable in Biomarker Assays? AAPS J 2022;24:65. [PMID: 35511303 DOI: 10.1208/s12248-022-00708-y] [Reference Citation Analysis]
3 Thankamony SP, Liu R, Peterson JE, Santockyte R, Olah T, Zhang Y. Calibrator material selection: a key criteria during biomarker assay method development. Bioanalysis 2021;13:787-96. [PMID: 33960820 DOI: 10.4155/bio-2020-0208] [Reference Citation Analysis]
4 Goodman J, Cowan KJ, Golob M, Karlsson L, Kunz U, Nelson R, Ulrichts H, Stevenson L, Terry L, Timmerman P. Update to the European Bioanalysis Forum recommendation on biomarkers assays; bringing context of use into practice. Bioanalysis 2020;12:1427-37. [PMID: 33025797 DOI: 10.4155/bio-2020-0243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]